Unknown

Dataset Information

0

In vitro activity of daptomycin in combination with ?-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.


ABSTRACT: Enterococci that are nonsusceptible (NS; MIC > 4 ?g/ml) to daptomycin are an emerging clinical concern. The synergistic combination of daptomycin plus beta-lactams has been shown to be effective against vancomycin-resistant Enterococcus (VRE) species in vitro. This study systematically evaluated by in vitro time-kill studies the effect of daptomycin in combination with ampicillin, cefazolin, ceftriaxone, ceftaroline, ertapenem, gentamicin, tigecycline, and rifampin, for a collection of 9 daptomycin-NS enterococci that exhibited a broad range of MICs and different resistance-conferring mutations. We found that ampicillin plus daptomycin yielded the most consistent synergy but did so only for isolates with mutations to the liaFSR system. Daptomycin binding was found to be enhanced by ampicillin in a representative isolate with such mutations but not for an isolate with mutation to the yycFGHIJ system. In contrast, ampicillin enhanced the killing of the LL-37 human antimicrobial peptide against daptomycin-NS E. faecium with either the liaFSR or yycFGHIJ mutation. Antagonism was noted only for rifampin and tigecycline and only for 2 or 3 isolates. These data add support to the growing body of evidence indicating that therapy combining daptomycin and ampicillin may be helpful in eradicating refractory VRE infections.

SUBMITTER: Hindler JA 

PROVIDER: S-EPMC4468720 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Hindler Janet A JA   Wong-Beringer Annie A   Charlton Carmen L CL   Miller Shelley A SA   Kelesidis Theodoros T   Carvalho Marissa M   Sakoulas George G   Nonejuie Poochit P   Pogliano Joseph J   Nizet Victor V   Humphries Romney R  

Antimicrobial agents and chemotherapy 20150511 7


Enterococci that are nonsusceptible (NS; MIC > 4 μg/ml) to daptomycin are an emerging clinical concern. The synergistic combination of daptomycin plus beta-lactams has been shown to be effective against vancomycin-resistant Enterococcus (VRE) species in vitro. This study systematically evaluated by in vitro time-kill studies the effect of daptomycin in combination with ampicillin, cefazolin, ceftriaxone, ceftaroline, ertapenem, gentamicin, tigecycline, and rifampin, for a collection of 9 daptomy  ...[more]

Similar Datasets

| S-EPMC4690039 | biostudies-literature
| S-EPMC8483151 | biostudies-literature
| S-EPMC1855505 | biostudies-literature
| S-EPMC4914619 | biostudies-literature
| S-EPMC3957885 | biostudies-other
| S-EPMC6963809 | biostudies-literature
| S-EPMC2737833 | biostudies-literature
| S-EPMC6105850 | biostudies-other
| S-EPMC8773184 | biostudies-literature
| S-EPMC2693502 | biostudies-literature